Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Transdermal N-0923 in Parkinson's Disease
NCT00001931Phase 2Completed
- Sponsor
- National Institute of Neurological Disorders and Stroke
- Start
- May 1999
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Parkinson's disease (PD) comparing N-0923 with Placebo (2 arms). Primary endpoint: Change in daily levodopa dose at 21 days. Started May 1999; status: completed.
02
Drugs
rotigotine
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT00001931.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00001931.